126results about How to "Avoid cytotoxicity" patented technology

The invention relates to a preparation method of injectable natural polysaccharide self-healing hydrogel. The preparation method of the injectable natural polysaccharide self-healing hydrogel comprises the following steps: firstly synthesizing water soluble N-carboxyethyl chitosan by carrying out a Michael addition reaction on acrylic acid and chitosan, carrying out an oxidization reaction on sodium periodate and sodium alginate to obtain oxidized sodium alginate, then carrying out a dehydration condensation reaction on N-carboxyethyl chitosan and oxidized sodium alginate and on adipic dihydrazide and oxidized sodium alginate in a phosphate buffer liquid at the temperature of 37 DEG C, so as to respectively generate invertible imine bond and acylhydrazone bond, and finally preparing injectable natural polysaccharide macromolecular hydrogel with self-healing property. The preparation method of the injectable natural polysaccharide self-healing hydrogel has the advantages that a synthetic process of the injectable self-healing hydrogel is simple and green, reaction conditions are mild, the injectable self-healing hydrogel can form gel in a physiological environment and has self-healing capability, and the injectable self-healing hydrogel has a good application prospect in the fields of drug sustained release and the like.

The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and/or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors).

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

A pharmaceutical composition for preventing or treating chronic inflammatory airway diseases comprising alpha-enolase protein as an active ingredient is provided. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing chronic inflammatory airway diseases comprising alpha-enolase protein. The present invention further provides a composition for screening a therapeutic agent for chronic inflammatory airway diseases, comprising one or more of alpha-enolase protein or autoantibodies to alpha-enolase obtained from patients with chronic inflammatory airway diseases, and a method for screening a therapeutic agent for chronic inflammatory airway diseases using this composition. The present invention still further provides methods for diagnosing, preventing or treating chronic inflammatory airway diseases using alpha-enolase protein.

Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.

The invention discloses a chitosan hydrogel. The structural unit of the chitosan hydrogel is shown in the specification; and in the structural unit, m is a natural number in a range of 400-700, and n is a natural number in a range of 30-100. The invention also discloses a preparation method of the chitosan hydrogel, and an application of the chitosan hydrogel. The method comprises the following steps: polyethylene glycol and tyramine molecules are grafted to a chitosan molecular chain in order to obtain a highly-water-soluble chitosan derivative, and the derivative is processed under the action of a crosslinking reagent to obtain the chitosan hydrogel. The process of the preparation method is simple, and the prepared chitosan hydrogel has the advantages of good physical, chemical and biological performances, good histocompatibility, environmental protection, and non-toxicity, and can be safely and effectively applied in restoration of wound tissues.

The invention provides a foreign gene-carrying recombinant virus vector efficiently produced in a packaging cell and a construction method and application thereof. The foreign gene-carrying recombinant virus vector is characterized in that at least one target point nucleotide sequence of the following micro RNA is inserted into the 3' non-translational zone of a foreign gene connected with a virus in an operable way; and the micro RNA expresses at a high level in a virus packaging cell, and does not express or expresses at a low level in a target cell. Therefore, the invention realizes the selective inhibition of the expression of the foreign gene in the virus packaging cell, avoids the negative effect of the foreign gene on the virus packaging and production, and improves the production efficiency and titer of the virus. Simultaneously, the invention can not lower the expression level of the foreign gene in the target cell, and can not affect the therapeutic effect or the research onthe function of the foreign gene.

The invention provides a whitening composition, whitening skin-brightening cream comprising the same and a preparation method thereof. The whitening skin-brightening cream is prepared from the following components in percent by mass: 0.1-20% of the whitening composition, 1-25% of a wetting agent, 1-5% of an emulsifier, 1-20% of skin-moistening grease, 0.1-5% of a skin conditioner, 0.05-3% of a permeation aid, 0.01-1% of a chelating agent, 0.1-1% of a thickener, 0-1% of essence, 0.05-2% of a preservative and the balance deionized water. The whitening composition is prepared from eight traditional Chinese medicinal material extraction solutions: ginseng, cortex mori radicis, angelica sinensis, glycyrrhiza, tea leaves, ganoderma atrum, rhodiola rosea and folium ginkgo as well as conventionalwhitening agents nicotinamide and tranexamic acid, and has the functions of whitening synergically and reducing irritation. The whitening skin-brightening cream moistens the skin and is not greasy, iseasy to absorb, and is obvious in whitening and skin-brightening effect.

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

The invention belongs to the technical field of genetic engineering, particularly relates to a genome editing method based on a zymomonas mobilis endogenous CRISPR-Cas system and application thereof and aims at taking Z.mobilis 4 as a type strain and utilizing the I-F type CRISPR-Cas system coded by its genome to establish a genome editing platform. A powerful tool is provided for basic research and application research in the strain and similar cells, and the development of metabolic engineering, system biology and synthetic biology is promoted. According to the technical scheme, the genome editing method is characterized by comprising the steps of constructing a plasmid containing an artificial CRISPR expression unit; selecting a guide RNA sequence aiming at a target site; constructing aguide RNA primer sequence on the plasmid containing the artificial CRISPR expression unit; constructing a donor DNA sequence on a vector to obtain an editing plasmid; transforming the editing plasmidinto competent cells for editing.

Maleimide and succinimide derivatives were found to be effective topoisomerase II catalytic inhibitors. Due to this property, the maleimide and succinimide derivatives were investigated for their use as cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other cytostatic agents, such as topoisomerase II poisons. The maleimide and succinimide derivatives, due to their effective topoisomerase II catalytic inhibitory activity, are also useful as extravasation agents, such as upon administration of a topoisomerase II poison.

The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1:

wherein in General formula 1, R₁ through R₃ independently represent a hydrogen atom or an appropriate substituent; Z₁ represents a heterocyclic ring and Z₂ represents the same or different heterocyclic or aromatic ring as in Z₁, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R₁ and R₂ do not exist when o is 0, while, when p is 0, R₃ does not exist and the binding between the carbon atom to which R₂ binds and Z₂ is a single bond; X₁⁻ represents an appropriate counter anion and q represents an integer of 1 or 2.

The invention discloses a culture medium capable of promoting the division growth of mesenchymal stem cells, which comprises a serum-free basic culture medium and an additive added on the basis of theserum-free basic culture medium, wherein the additive comprises a hibiscus mutabilis extract, seaweed polysaccharide, astragaloside IV, human serum albumin, transferrin, glutamine, platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and vitamin A; the hibiscus mutabilis extract has antioxidant and cell activating activity, and can effectively promote the growth of cell metabolic by compounding seaweed polysaccharide and astragaloside IV; human serum albumin, transferrin, glutamine and vitamin A provide essential nutrient substances for the growth of stem cells; platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and other cytokines together promote the rapid growth and proliferation ofstem cells; the culture medium not only can improve the growth activity of mesenchymal stem cells, shorten the culture time, promote the expression of cell growth factors, but also can maintain the stem cell activity of the differentiation potential of mesenchymal stem cells; stem cells are not differentiated in daily culture, thereby providing convenience for scientific research.

Disclosed is a cyclophilin protein with PPIase activity functioning as an antioxidant. When being overexpressed in transplanted cells, the cyclophilin protein remarkably reduces the cytotoxicity induced by cyclosporin A or its analogues so that it can greatly improve the success rate in transplantation. Also, disclosed is a composition useful to prevent transplant rejection, comprising a recombinant expression vector which can over-express a cyclophilin protein with PPIase activity. The recombinant expression vector is introduced into cells which are thus transformed to be resistant to cyclosporin A and its analogues. A method of preparing such cells is also disclosed.

The invention relates to a method for amplifying autologous bone marrow mesenchymal stem cells, in particular to the purpose of finding out the optimal environment for cell growth by utilizing the compound of culture media and a little of autoserum as well as the purpose of strictly controlling the cell fusion degree in the method so as to achieve the purpose of fast culturing the bone marrow mesenchymal stem cells in the end; and the use of the autoserum remedies the defects of fetal calf serum. The culture time of the bone marrow mesenchymal stem cells is greatly shortened, thereby being beneficial to clinical application. Simultaneously, the method is used for culturing the bone marrow mesenchymal stem cells, and 1.5-2*107 mesenchymal stem cells can be obtained through amplification innearly twenty days by extracting 5 ml bone marrow. The dosage of blood serum is greatly reduced, thereby reducing the quantity of blood collected from patients. The obtained bone marrow mesenchymal stem cells have the characteristics of the stem cells in the aspects of cell morphology, growth cycle, phenotype, inducing differentiation capacity, and the like.

The invention belongs to the field of medical materials for tendon injury repair and discloses a polycaprolactone/methylacryloyl elastin nanofiber composite membrane and a preparation method and application thereof. The preparation method specifically comprises the following steps of grafting methacrylic anhydride to elastin to obtain the methylacryloyl elastin; then mixing polycaprolactone with the methylacryloyl elastin uniformly to prepare a spinning solution; carrying out electrostatic spinning by using the spinning solution to obtain a composite membrane; and soaking the composite membrane by using a photoinitiator solution, carrying out photo-crosslinking under ultraviolet light and then carrying out washing and drying for many times to obtain the polycaprolactone/methylacryloyl elastin nanofiber composite membrane. The preparation method is easy to operate and relatively low in production cost, and the obtained composite membrane is good in mechanical property and biocompatibility and can be used for tendon tissue engineering and tissue repair.

The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.